Navigation Links
Groupe Athena, Inc. Clarifies Previous Guidance

MUMBAI, India, Aug. 24, 2011 /PRNewswire/ -- Groupe Athena, Inc. (Pink Sheets: GATA) announced on August 15, 2011 they have approximately $60 million in customer orders that they are currently processing, and they are expecting this number to increase in the near term.  Based on the orders in hand the company expects to be able to convert at least two thirds or approximately $40 million into revenue during the current fiscal year.

The company also stated that due to the recent capital investments in equipment and facilities which has increased their ability to perform more services in-house, they will to be able to increase net profit margins on future revenues by 1.5-2%. To clarify this projection the company issued the following example:

Approximate current hourly rate for outsourcing of tests: $1,750

Approximate In-house hourly rate for same process:       $3-400

Based on this scenario the company expects to reduce these costs up to 80% over current levels.

The resulting savings to net earnings would have added several hundred thousand dollars to fiscal 2011 net earnings and will have a positive impact on any future earnings.

The company is on track to report revenue of $12,000,000 for the current quarter, which would be more than the first and second quarters combined of the previous fiscal year and well in line with their expectations for the current fiscal year.

The company is still committed to funding all capital expenditures entirely from internal cash accruals without any further dilution or debt increases.

As was previously stated, the Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

About Groupe Athena, Inc.

Groupe Athena, Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.

The company has a research and marketing facility in India that currently employs 15 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company's web address is

For more information contact:
Paul Cornell
Corporate Shareholder Relations, Inc.

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate", "project", "intend", "forecast", "anticipate", "plan", "planning", "expect", "believe", "will likely", "should", "could", "would", "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets.

SOURCE Groupe Athena, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Groupe Athena, Inc. Provides Guidance on Current Orders
2. Groupe Athena, Inc. Profits Soar on Record Revenues
3. Aethlon Medical Clarifies News Report
4. Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend
5. BioCryst Clarifies Government Declaration Regarding Peramivir
6. Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord
7. New Research Validates Results of Previous Studies Demonstrating Tru-D® (Lumalier Corporation) Significantly Reduces Environmental Contamination on Surfaces in Patient Rooms
8. ZALTRAP™ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
9. NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
10. Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients
11. Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Post Your Comments:
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Un nuevo enfoque combina la inmunoterapia con la terapia ... Clinical Cancer Research . --> ...
(Date:11/26/2015)... , Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met ... kanker. ) ...      (Photo: ) ... Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ... is expected to boost the market growth, as 3D bioprinting ... --> 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... ... Beginning November 30th at 6:00 a.m. EST until 11:59 p.m. EST, customers ... up to 20% off orders $80 or more to free gifts with purchases, there will ... As a competitive e-commerce website for skin care and cosmetic needs, customers will save on ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... they are handling security in light of the recent terrorist attacks in Paris, other ... to stop an attack from reaching U.S. soil. Especially around special events that may ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special ... 10% off of their purchase of lice treatment product. In addition, customers will receive ... a company spokesperson. “Finding lice is a sure way to ruin the holidays, so ...
(Date:11/27/2015)... ... 27, 2015 , ... Intellitec Solutions announced today that they ... Recognized as Microsoft’s official group for end users of Dynamics SL ERP software, ... industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment to ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... successful and prominent nonprofit healthcare organizations in the country. They have overseen financial ... organizations, and helped advance the healthcare industry as a whole through their advocacy ...
Breaking Medicine News(10 mins):